Pilgrim Global buys Sable Offshore (SOC) shares worth $14.7m
Investing.com -- GRAIL, Inc. (NASDAQ:GRAL) stock surged 20% on Thursday after announcing a strategic collaboration with Samsung to bring its Galleri multi-cancer early detection test to key Asian markets.
The partnership involves a $110 million equity investment from Samsung C&T and Samsung Electronics at $70.05 per share, subject to closing conditions. Under the agreement, Samsung C&T will serve as the exclusive distributor for GRAIL’s Galleri test in South Korea, with potential expansion into Japan and Singapore.
"We look forward to partnering with Samsung to bring multi-cancer early detection to Asia, beginning in South Korea," said Sir Harpal Kumar, President of International Business & Biopharma at GRAIL. "Samsung’s significant equity investment strengthens our balance sheet and provides further cash runway as we advance through key milestones to secure reimbursement for Galleri in the U.S. and key international markets."
The companies also plan to explore additional collaborations, including genomic-lifestyle clinical research and integration of Samsung Electronics’ health data platform with GRAIL’s technologies.
Commercial operations are expected to begin shortly after the definitive agreements are finalized, which is anticipated in early 2026. The investment is subject to customary closing conditions and regulatory approvals.
GRAIL’s Galleri test is designed to detect multiple types of cancer in early stages when treatment options are potentially more effective.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.